#Balversa
LightNews LightNews
skelterjohn.bsky.social
Today I begin a clinical trial for a medication called vepugratinib. It's like balversa, but more targeted. I had a really good response with a short stint of balversa, so I'm hoping this can be my long term ok ish solution.
October 1, 2026 at 3:17 PM
infarmed-ip.bsky.social
Relatório de avaliação de financiamento público |
Balversa (erdafitinib)💊

Saiba mais: 🔗 swki.me/thWbz5vx

#infarmed #medicamentos #financiamentopublico #balversa
May 11, 2026 at 3:35 PM
dengyuemedicine.bsky.social
El inhibidor de FGFR de Johnson & Johnson, erdafitinib es aprobado para su comercialización en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Erdafitinib #Balversa #JohnsonAndJohnson #FGFR #FGFR3 #UrothelialCarcinoma #Oncología
January 13, 2026 at 7:01 AM
4040rec.bsky.social
#bladdercancer #NICErecommended #JnJ #Balversa #urothelialcancer #geneticalteration #erdafitinib #FGFR3alteration #unresectableurothelialcancer #metastaticurothelialcancer #THOrclinicaltrial #FGFR3expressingcancercellgrowth #genetictesting
pharmatimes.com/news/first-t...
First treatment for common bladder cancer recommended by NICE - PharmaTimes
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
pharmatimes.com
April 15, 2025 at 8:56 AM
pharmaphorum.bsky.social
NEWS: Find out about a new oral, take-at-home drug for bladder cancer this is now available via the NHS.
pharmaphorum.com/news/home-ta...
At-home tablet now an option for NHS bladder cancer patients
The first targeted drug for a common form of bladder cancer that can be taken at home. J&J's Balversa, has been backed for NHS use
pharmaphorum.com
April 10, 2025 at 1:12 PM
paulwalker44.bsky.social
Some examples of the cost of specific cancer treatments include: • Atezolizumab (Tecentriq): Costs nearly $14,000 per month for lung, bladder, and liver cancer • Erdafitinib (Balversa): Costs between $10,000 and $22,000 per month for bladder cancer • Polatuzumab vedotin-piiq (Polivy): Costs $90,000 for a four-month course for a type of non-Hodgkin lymphoma • Yescarta: Costs $373,000 for one dose for the treatment of non-Hodgkin lymphoma • Kymriah: Costs $475,000 for one treatment course for acute lymphoblastic leukemia
September 15, 2024 at 2:42 PM
longtail-news.bsky.social
Feed: "PharmaTimes"
By: Ella Day on Thursday, April 10, 2025
First treatment for common bladder cancer recommended by NICE
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
pharmatimes.com
April 10, 2025 at 6:06 PM
lequotidiendupharmacien.fr
En oncohématologie, Tibsovo est indiqué chez des patients ayant une leucémie aiguë myéloïde ou un cancer des voies biliaires.
Tibsovo et Balversa : deux nouveaux anticancéreux oraux disponibles en officine
En oncohématologie, Tibsovo est indiqué chez des patients ayant une leucémie aiguë myéloïde ou un cancer des voies biliaires (cholangiocarcinome). Tibsovo 250 mg comprimé pelliculé contient de l’ivosidénib, un nouveau principe actif...
www.lequotidiendupharmacien.fr
November 22, 2025 at 9:20 AM
beyondlink.bsky.social
Natco Pharma gets U.S. FDA tentative nod for generic of Janssen’s cancer drug
Natco Pharma gets U.S. FDA tentative nod for generic of Janssen’s cancer drug
Natco Pharma has received U.S. Food and Drug Administration’s tentative approval for Erdafitinib Tablets 3 mg, 4mg, and 5 mg, a generic version of Janssen Biotech cancer drug Balversa. Erdafitinib tab...
beyondlink.live
February 3, 2026 at 7:19 PM
infosalus.com
Llega a España 'Balversa', un tratamiento oral para carcinoma urotelial avanzado con alteraciones del FGFR3
Llega a España 'Balversa', un tratamiento oral para carcinoma urotelial avanzado con alteraciones del FGFR3
www.infosalus.com
June 25, 2025 at 2:15 AM
jjorgepoveda.bsky.social
La AEMPS emite un IPT para Balversa, autorizado para adultos con carcinoma urotelial irresecable o metastásico elglobalfarma.com/politica/ipt...
La AEMPS emite un IPT para Balversa, autorizado para adultos con carcinoma urotelial irresecable o metastásico
El informe avale su uso en pacientes portadores de alteraciones genéticas específicas FGFR3 que hayan recibido al menos una línea de tratamiento con un inhibidor de PD-1 o PD-L1.
elglobalfarma.com
June 25, 2025 at 1:50 PM
pwk2024.bsky.social
Three (3) Sustaining Innovation #PostDoc opportunities in fragment-based design at Astex Pharmaceuticals (Cambridge UK) ref: SI/0825 | closing: 30-Sep-2025 #FBD #FBDD #SBDD #MedChem #ChemBiol #StructBiol #ChemPostDoc #PostDocJobs #chemsky 🧪
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
Astex Careers Astex Careers
Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ partnered with AstraZeneca). Astex continues to grow and focuses on Neurological Disorders and Oncology.
www.cloudonlinerecruitment.co.uk
September 5, 2025 at 7:54 AM
pwk2024.bsky.social
Opportunity for laboratory-based medicinal chemist at Astex Pharmaceuticals (Cambridge UK) ref: MC/0825 | closing: 30-Sep-2025 #MedChem #SynChem #UKChemJobs #ChemJobs #chemsky 🧪
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
Astex Careers Astex Careers
Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery (FBDD) platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ partnered with AstraZeneca). We have several opportunities for talented scientists who are committed to developing treatments for patients with Cancer and Neurological Disorders.
www.cloudonlinerecruitment.co.uk
August 19, 2025 at 6:50 AM
drtimos.bsky.social
Thoughts on this? >> #ASCOGU: Lilly’s early bladder cancer data hint at safety
edge over J&J’s Balversa: Eli Lilly has shared first-in-human results for its selective FGFR3… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa
Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson & Johnson’s Balversa. Balversa is marketed ...
dlvr.it
February 15, 2025 at 12:41 AM